Recently reviewed and data from peer -reviewed studies, expert meta-analyzes, and epidemiological analyzes have demonstrated favorable outcomes for Ivermectin as a treatment for COVID-19. Ivermectin is an antiparasite drug with proven antiviral and anti-inflammatory properties. As of December 2020, a large number of evidence-based data have demonstrated the efficacy and safety of the use of Ivermectin in the prevention and treatment of COVID-19.
Several preclinical studies of Ivermectin against SARS-CoV-2 as an antiviral and anti-inflammatory agent have been successful in demonstrating its effectiveness. Various studies have shown that Ivermectin inhibits the replication of many RNA viruses such as Zika, HIV, Dengue, and SARS-CoV-2, due to its antiviral properties. Various mechanisms have been proposed for antiviral properties, such as the ability to bind the spike protein to the virus and prevent cellular virus entry, or by preventing and suppressing virus replication.
A more inflammatory response associated with severe COVID-19. A number of studies have also demonstrated the anti-inflammatory properties of Ivermectin. Because of its ability to inhibit the production of cytokines and the translation of nuclear factor-kB (NF-kB), which are potent mediators of inflammation.
Various randomized controlled trials and controlled controlled studies around the world have shown a significant reduction in COVID-19 transmission when participants were treated with Ivermectin. One such study was conducted at Zagazig university in Egypt. Patients were treated with ivermectin on the day they received a positive COVID-19 test and 72 hours after the test. A significant reduction in COVID-19 symptoms was observed after the two-week period. Data published in The International Journal of Antimicrobial Agent compared data from countries where Ivermectin was actively used which found that the case of COVID-19 was much shorter in those countries.
From analyzes of eight available clinical trials, it was concluded that there was a statistically significant reduction in viral enrollment when Ivermectin was used as a prophylactic treatment for COVID-19.
19 other clinical trials have shown significant effects related to recovery, reduced length of hospital stay, reduced viral load, and reduced mortality when Ivermectin was used for the treatment of COVID-19. When it comes to side effects, most of them are mild and transient.
Considering all these consequences, recently, the British Ivermectin Recommendation Panel in conjunction with Unitaid / WHO strongly recommended the use of Ivermectin for the treatment and prevention of COVID-19.
Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of External Evidence Demonstrating the Effectiveness of Ivermectin in the Prophylaxis and Treatment of COVID-19. Am J Ther. 2021; 28 (3): e299-e318. Published 2021 April 22. doi: 10.1097 / MJT.0000000000001377
Portrait of Miguel Á. Ninong from the pixel